China Biopharma Inc. Completes Its Name Change.

PRINCETON, N.J. -- China Biopharma, Inc. (CBPC.OB) is pleased to announce that the Company has changed its name and stock symbol recently. The new trading symbol is "CBPC.OB".

The new company name is better associated with the industry and market the company conducts its business in. "We are delighted to have our new name and new stock symbol now. They are more accurately reflecting the Company's core business," commented Peter Wang, CEO of China Biopharma Inc.

About China Biopharma Inc.

China Biopharma is a fast growing developer, producer and distributor of human vaccine products in China. It has two operating subsidiaries in China, Zhejiang Tianyuan Biotech Co., Ltd. and Hainan CITIC Biopharmaceutical Development Co., Ltd. The Company's current products consist of human vaccines against influenza, hemorrhagic fever, and Japanese Encephalitis. With its investment and ownership of local Chinese biopharmaceutical companies and the partnership with international vaccine providers, the Company plans to build a leading biopharmaceutical company in China by leveraging its manufacturing and marketing capabilities and introducing advanced technologies, best products, and an experienced management team. For more information, visit its website at www.chinabiopharma.com.cn.

Safe Harbor Statement

Some of the statements made in this press release discuss future events and developments, including the Company's future business strategy and its ability to generate revenue, income and cash flow, and should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements can generally be identified by words such as "expect," "anticipate," "believe," "estimate," "intend," "plan," and similar expressions. These statements involve a high degree of risk and uncertainty that exists in the Company's operations and business environment and are subject to change based on various factors that could cause actual Company results, performance, plans, goals and objectives to differ materially from those contemplated or implied in these forward-looking statements. Actual results may be different from anticipated results for a number of reasons, including the Company's new and uncertain business model, uncertainty regarding acceptance of the Company's products and services and the Company's limited operating history.